You are here

Novo Nordisk

IP trouble defers launch of Novo's long-acting hemophilia therapy

IP trouble defers launch of Novo's long-acting hemophilia therapy

Endpoints

Flag link:

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

BioSpace

Flag link:

An oral insulin delivery system inspired by tortoises

An oral insulin delivery system inspired by tortoises

Fierce Biotech

Brigham and Women's

Flag link:

Mark Your Calendar For These February PDUFA Dates

Mark Your Calendar For These February PDUFA Dates

Yahoo/Benzinga

MOTIF BIO PLC/S ADR

Flag link:

Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing

Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns over Drug Pricing

BioSpace

Flag link:

Novo bets on swift FDA review for oral diabetes drug semaglutide

Novo bets on swift FDA review for oral diabetes drug semaglutide

Endpoints

Flag link:

On heels of drug pricing hearings, Democratic lawmakers kick off insulin probe

On heels of drug pricing hearings, Democratic lawmakers kick off insulin probe

Fierce Pharma

Flag link:

Novo Holdings' antibiotic resistance fund backs 3 biotechs

Novo Holdings' antibiotic resistance fund backs 3 biotechs

Fierce Biotech

antibiotic resistance

Procarta Biosystems

Entasis Therapeutics

Flag link:

Novo Nordisk’s first diabetes innovation challenge winners head to the lab

Novo Nordisk’s first diabetes innovation challenge winners head to the lab

Fierce Pharma

Flag link:

3 Biotechs With Potential Blockbusters Near the Finish Line

3 Biotechs With Potential Blockbusters Near the Finish Line

Motley Fool

Vertex Pharmaceuticals

VX-659 + tezacaftor + ivacaftor

Flag link:

Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline

Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline

Fierce Biotech

Staten Biotechnology

Flag link:

Novo taps e-therapeutics for diabetes target discovery drive

Novo taps e-therapeutics for diabetes target discovery drive

Fierce Biotech

drug development

Flag link:

Novo keeps adding capacity, and jobs, to its North Carolina drug plant

Novo keeps adding capacity, and jobs, to its North Carolina drug plant

Fierce Pharma

drug manufacturing

Flag link:

Novo Nordisk’s diabetes pill clears cardiac safety hurdle

Novo Nordisk’s diabetes pill clears cardiac safety hurdle

Pharmaforum

type 2 diabetes

clinical trials

cardiovascular outcomes

Flag link:

Novo Nordisk staff cull swells to 1,300

Novo Nordisk staff cull swells to 1,300

Pharmaforum

artificial intelligence

Flag link:

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium

Endpoints

Aeterna Zentaris

adult growth hormone deficiency

Flag link:

Digital diabetes mavens Novo Nordisk and Sanofi top new patient experience ranking

Digital diabetes mavens Novo Nordisk and Sanofi top new patient experience ranking

Fierce Pharma

patient experience data

type 2 diabetes

Flag link:

Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices

Minnesota takes aim at Sanofi, Novo, Lilly for insulin prices

Biopharma Dive

Flag link:

Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs

Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs

CP Wire

type 2 diabetes

Flag link:

Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs

type 2 diabetes

Flag link:

Pages